TIGIT and neoplasm: A recent report showed that a single CD-155/TIGIT (T cell immuno77receptor with Ig and ITIM domains) or PD-1/PD-L1 (Programmed death-1/Programmed death Ligand 1) blockade has limited anti-tumor effects [95].